These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 27582001)

  • 41. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
    Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
    Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen.
    Lupold SE; Rodriguez R
    Mol Cancer Ther; 2004 May; 3(5):597-603. PubMed ID: 15141017
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
    Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L
    J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner.
    Taylor RM; Sillerud LO
    Int J Nanomedicine; 2012; 7():4341-52. PubMed ID: 22915856
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer.
    Morgenroth A; Tinkir E; Vogg ATJ; Sankaranarayanan RA; Baazaoui F; Mottaghy FM
    Breast Cancer Res; 2019 Oct; 21(1):116. PubMed ID: 31640747
    [TBL] [Abstract][Full Text] [Related]  

  • 46. (R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.
    Gourni E; Canovas C; Goncalves V; Denat F; Meyer PT; Maecke HR
    PLoS One; 2015; 10(12):e0145755. PubMed ID: 26700033
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
    Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
    Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacious delivery of protein drugs to prostate cancer cells by PSMA-targeted pH-responsive chimaeric polymersomes.
    Li X; Yang W; Zou Y; Meng F; Deng C; Zhong Z
    J Control Release; 2015 Dec; 220(Pt B):704-14. PubMed ID: 26348387
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis and evaluation of a novel urea-based
    Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
    Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
    Wang X; Ma D; Olson WC; Heston WD
    Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.
    Ngen EJ; Chen Y; Azad BB; Boinapally S; Jacob D; Lisok A; Shen C; Hossain MS; Jin J; Bhujwalla ZM; Pomper MG; Banerjee SR
    Nanotheranostics; 2021; 5(2):182-196. PubMed ID: 33564617
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer.
    Schatz CA; Zitzmann-Kolbe S; Moen I; Klotz M; Nair S; Stargard S; Bjerke RM; Wickstrøm Biseth K; Feng YZ; Indrevoll B; Cruciani V; Karlsson J; Haendler B; Nielsen CH; Alfsen MZ; Hammer S; Hennekes H; Cuthbertson A; Hagemann UB; Larsen Å
    Clin Cancer Res; 2024 Jun; 30(11):2531-2544. PubMed ID: 38593212
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
    Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
    Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen.
    Wang X; Tsui B; Ramamurthy G; Zhang P; Meyers J; Kenney ME; Kiechle J; Ponsky L; Basilion JP
    Mol Cancer Ther; 2016 Aug; 15(8):1834-44. PubMed ID: 27297866
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA).
    Patil Y; Shmeeda H; Amitay Y; Ohana P; Kumar S; Gabizon A
    Nanomedicine; 2018 Jun; 14(4):1407-1416. PubMed ID: 29680672
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of short-term Dutasteride treatment on prostate-specific membrane antigen expression in a mouse xenograft model.
    Kranzbühler B; Sousa R; Prause L; Burger IA; Rupp NJ; Sulser T; Salemi S; Eberli D
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1418. PubMed ID: 34008909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles.
    Kasten BB; Liu T; Nedrow-Byers JR; Benny PD; Berkman CE
    Bioorg Med Chem Lett; 2013 Jan; 23(2):565-8. PubMed ID: 23232055
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
    Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
    Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative [Fe]MRI determination of the dynamics of PSMA-targeted SPIONs discriminates among prostate tumor xenografts based on their PSMA expression.
    Sillerud LO
    J Magn Reson Imaging; 2018 Aug; 48(2):469-481. PubMed ID: 29331081
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetically-engineered anti-PSMA exosome mimetics targeting advanced prostate cancer in vitro and in vivo.
    Severic M; Ma G; Pereira SGT; Ruiz A; Cheung CCL; Al-Jamal WT
    J Control Release; 2021 Feb; 330():101-110. PubMed ID: 33333118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.